Miracle Mile Advisors LLC Has $1.33 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Miracle Mile Advisors LLC grew its position in Amgen Inc. (NASDAQ:AMGNFree Report) by 37.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,611 shares of the medical research company’s stock after purchasing an additional 1,264 shares during the period. Miracle Mile Advisors LLC’s holdings in Amgen were worth $1,328,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Southland Equity Partners LLC raised its holdings in Amgen by 2.3% in the fourth quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after purchasing an additional 34 shares during the period. Acropolis Investment Management LLC increased its position in shares of Amgen by 3.5% during the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after acquiring an additional 34 shares in the last quarter. Opal Wealth Advisors LLC increased its position in shares of Amgen by 1.9% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock worth $538,000 after acquiring an additional 34 shares in the last quarter. FORVIS Wealth Advisors LLC increased its position in shares of Amgen by 1.4% during the fourth quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock worth $743,000 after acquiring an additional 35 shares in the last quarter. Finally, Evanson Asset Management LLC increased its position in shares of Amgen by 2.1% during the fourth quarter. Evanson Asset Management LLC now owns 1,666 shares of the medical research company’s stock worth $480,000 after acquiring an additional 35 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ AMGN opened at $283.04 on Tuesday. The firm has a 50-day moving average of $289.21 and a 200-day moving average of $281.19. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market cap of $151.69 billion, a PE ratio of 22.66, a P/E/G ratio of 2.69 and a beta of 0.58. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the company posted $4.09 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Analyst Ratings Changes

AMGN has been the subject of several research reports. Royal Bank of Canada increased their price objective on shares of Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Daiwa Capital Markets raised shares of Amgen from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $264.00 to $320.00 in a research report on Thursday, December 21st. UBS Group decreased their target price on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research report on Monday, January 29th. Morgan Stanley decreased their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. Finally, StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $295.30.

Read Our Latest Stock Analysis on AMGN

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Read More

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.